Angiotensin II receptor blocker-associated angioedema: On the heels of ACE inhibitor angioedema

被引:60
作者
Abdi, R
Dong, VM
Lee, CJ
Ntoso, KA
机构
[1] Brigham & Womens Hosp, Div Renal, Boston, MA 02115 USA
[2] Solvay Pharmaceut, Clin Operat & Med Affairs, Marietta, GA USA
[3] Montgomery Gen Hosp, Div Cardiol, Olney, MD USA
[4] Univ Penn Hlth Syst, Div Nephrol, Penn Hosp, Philadelphia, PA USA
来源
PHARMACOTHERAPY | 2002年 / 22卷 / 09期
关键词
D O I
10.1592/phco.22.13.1173.33517
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Angioedema and cough are known side effects of angiotensin-converting enzyme (ACE) inhibitors. Angiotensin-converting enzyme is a potent inhibitor of kinase II, which facilitates the breakdown of bradykinin. An increase in bradykinin levels results in continued prostaglandin E-2 synthesis, vasodilation, increased vascular permeability, and increased interstitial fluid. In contrast, the angiotensin II receptor blockers (ARBs) do not increase bradykinin levels. Angioedema as a complication of ACE inhibitor therapy is not widely recognized; this complication is even less recognized with second-line ARBs. We report angioedema associated with losartan (an ARB) in a patient who had experienced angioedema secondary to enalapril (an ACE inhibitor). Almost half of patients with ARB-associated angioedema also had developed angioedema while receiving ACE inhibitor therapy. Clinicians should exercise caution when using ARBs in patients with a history of angioedema secondary to ACE inhibitors.
引用
收藏
页码:1173 / 1175
页数:3
相关论文
共 24 条